Wynne Katie, Bloom Stephen R
Department of Metabolic Medicine, Imperial College London, and Hammersmith Hospital, UK.
Nat Clin Pract Endocrinol Metab. 2006 Nov;2(11):612-20. doi: 10.1038/ncpendmet0318.
Oxyntomodulin and peptide tyrosine-tyrosine (PYY) are released from intestinal enteroendocrine cells in response to a meal. These circulating hormones are considered to be satiety signals, as they have been found to decrease food intake, body weight and adiposity in rodents. Their effect on energy homeostasis is mediated by the hypothalamus and brainstem, and several studies have demonstrated alterations in neuropeptide signaling within the arcuate nucleus. The weight loss that has been observed in animal models after repeated administration of oxyntomodulin and PYY has led to interest in developing these peptides as antiobesity therapies in humans. Indeed, preliminary studies have found that oxyntomodulin or PYY administration reduces food intake and body weight effectively in overweight human volunteers. This research suggests that modulation of these gut hormones could prove to be effective long-term therapies in the quest to combat the obesity epidemic.
进餐时,胃泌酸调节素和酪酪肽(PYY)从肠道内分泌细胞释放。这些循环激素被认为是饱腹感信号,因为它们已被发现在啮齿动物中可减少食物摄入量、体重和肥胖程度。它们对能量平衡的影响由下丘脑和脑干介导,并且多项研究已证明弓状核内神经肽信号传导存在改变。在动物模型中,反复给予胃泌酸调节素和PYY后观察到体重减轻,这引发了人们将这些肽开发为人类抗肥胖疗法的兴趣。事实上,初步研究发现,给予胃泌酸调节素或PYY可有效降低超重人类志愿者的食物摄入量和体重。这项研究表明,调节这些肠道激素可能被证明是对抗肥胖流行的有效长期疗法。